Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Dostarlimab plus chemo prolongs survival in advanced dMMR/MSI-H endometrial cancer
02 Jul 2026
bởiStephen Padilla
Treatment with dostarlimab combined with carboplatin and paclitaxel (CP) confers sustained long-term progression-free survival (PFS) and overall survival (OS) benefits on patients with primary advanced or recurrent deficient mismatch repair and microsatellite instability-high (dMMR/MSI-H) endometrial cancer, as shown by the results of the phase III RUBY trial.
02 Jul 2026

Denosumab superior to alendronate for BMD loss prevention in malignant lymphoma
01 Jul 2026
bởiStephen Padilla
The use of denosumab demonstrates superior protection against bone mineral density (BMD) loss at 12 months compared with alendronate in older patients with newly diagnosed lymphoma receiving R-CHOP* and related regimens, as shown in the DENOSULY study.
01 Jul 2026






